Statistics for Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Total visits
views | |
---|---|
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study | 187 |
Total visits per month
views | |
---|---|
May 2024 | 0 |
June 2024 | 0 |
July 2024 | 0 |
August 2024 | 0 |
September 2024 | 0 |
October 2024 | 0 |
November 2024 | 0 |
File Visits
views | |
---|---|
10120_2018_Article_909.pdf | 277 |
Top country views
views | |
---|---|
United States | 129 |
Germany | 21 |
Ukraine | 4 |
China | 3 |
United Kingdom | 3 |
Canada | 2 |
Chile | 2 |
India | 1 |
Malaysia | 1 |
Portugal | 1 |
Russia | 1 |
Sweden | 1 |
Top city views
views | |
---|---|
Wilmington | 51 |
Fairfield | 20 |
Houston | 13 |
Kiez | 10 |
Gunzenhausen | 9 |
Cambridge | 5 |
Jacksonville | 5 |
Kiev | 4 |
Ann Arbor | 3 |
Dearborn | 3 |
Nürnberg | 2 |
San Francisco | 2 |
Toronto | 2 |
Baltimore | 1 |
Brooklyn | 1 |
Duncan | 1 |
Huaian | 1 |
Indianapolis | 1 |
Kansas City | 1 |
Linda-a-velha | 1 |
Moscow | 1 |
Mumbai | 1 |
Quzhou | 1 |
Scottsdale | 1 |
Seremban | 1 |
Stockholm | 1 |
Washington | 1 |